SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice

被引：0
|
作者：
John Wilding
Kevin Fernando
Nicola Milne
Marc Evans
Amar Ali
Steve Bain
Debbie Hicks
June James
Philip Newland-Jones
Dipesh Patel
Adie Viljoen
机构：
[1] University of Liverpool,Obesity and Endocrinology Research
[2] North Berwick Health Centre,Department of Diabetes
[3] CODES (COmmunity Diabetes Education and Support),Diabetes Research Unit Cymru
[4] University Hospital Llandough,Department of Diabetes and Endocrinology
[5] Oakenhurst Medical Practice,Department of Metabolic Medicine/Chemical Pathology
[6] Swansea University,undefined
[7] Barnet,undefined
[8] Enfield and Haringey Mental Health Trust,undefined
[9] University Hospitals of Leicester NHS Trust,undefined
[10] University Hospitals Southampton NHS Foundation Trust,undefined
[11] Royal Free NHS Foundation Trust,undefined
[12] Lister Hospital,undefined
来源：
Diabetes Therapy | 2018年 / 9卷
关键词：
Clinical guidance; Glucose-lowering medicines; Oral glucose-lowering medicines; Prescribing tools; Risk/benefit; SGLT2 inhibitors; Therapy choice; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1757 / 1773
页数：16
相关论文
共 50 条
  • [21] Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes
    Muskiet, Marcel H. A.
    van Bommel, Erik J. M.
    van Raalte, Daniel H.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (03): : 188 - 189
  • [22] SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
    Saisho, Yoshifumi
    DISEASES, 2020, 8 (02)
  • [23] The role of SGLT2 inhibitors in managing type 2 diabetes
    Tat, Velen
    Forest, Christopher P.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2018, 31 (06): : 35 - 40
  • [24] Why are SGLT2 inhibitors a good choice in the management of Type 2 Diabetes Mellitus?
    Ghazanfar, Nhila
    WORLD FAMILY MEDICINE, 2021, 19 (07): : 86 - 88
  • [25] The Clinical Efficacy and Safety of SGLT2 Inhibitors in Japanese Patients with Type 2 Diabetes
    Tosaki, Takahiro
    Kamiya, Hideki
    Kato, Yoshiro
    Kondo, Masaki
    Nakamura, Jiro
    DIABETES, 2015, 64 : A154 - A155
  • [26] SGLT2 inhibitors in Type 1 diabetes: is this the future?
    Herring, R.
    Russell-Jones, D. L.
    DIABETIC MEDICINE, 2018, 35 (12) : 1642 - 1643
  • [27] Effects of SGLT2 inhibitors on clinical cancer survival in patients with type 2 diabetes
    Huang, Yen-Min
    Chen, Wan-Ming
    Jao, An-Tzu
    Chen, Mingchih
    Shia, Ben-Chang
    Wu, Szu-Yuan
    DIABETES & METABOLISM, 2024, 50 (01)
  • [28] SGLT2 inhibitors and heart failure — clinical implications
    Itamar Raz
    Avivit Cahn
    Nature Reviews Cardiology, 2016, 13 : 185 - 186
  • [29] SGLT2 inhibitors and heart failure - clinical implications
    Raz, Itamar
    Cahn, Avivit
    NATURE REVIEWS CARDIOLOGY, 2016, 13 (04) : 185 - 186
  • [30] SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
    Davidson, Jaime A.
    POSTGRADUATE MEDICINE, 2019, 131 (04) : 251 - 260
12345